Akari Therapeutics

Yahoo Finance • 5 days ago

European Equities Traded in the US as American Depositary Receipts Little Changed in Wednesday Trading

European equities traded in the US as American depositary receipts were little changed Wednesday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 dri... Full story

Yahoo Finance • 10 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

European equities traded in the US as American depositary receipts were tracking higher Thursday mor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 12 days ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed a provisional pat... Full story

Yahoo Finance • 17 days ago

European Equities Traded in the US as ADRs Fall in Friday Trading

European equities traded in the US as American depositary receipts fell late Friday morning with the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 24 days ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President... Full story

Yahoo Finance • 26 days ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immu... Full story

Yahoo Finance • last month

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announ... Full story

Yahoo Finance • 2 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Watch the “What This Means” video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADC... Full story

Yahoo Finance • 2 months ago

Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload

BOSTON/LONDON - Akari Therapeutics, Plc (NASDAQ:AKTX), a small-cap biotech company with a market capitalization of $37 million, is continuing research on its novel spliceosome modulator payload PH1, which has demonstrated potential to inhi... Full story

Yahoo Finance • 2 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new p... Full story

Yahoo Finance • 2 months ago

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today an... Full story

Yahoo Finance • 2 months ago

Maxim Group initiates coverage on Akari Therapeutics stock with Buy rating

Investing.com - Maxim Group initiated coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and a $5.00 price target on Friday. The stock, currently trading at $1.13 with a market capitalization of $37 million, is showing potentia... Full story

Yahoo Finance • 3 months ago

Akari Therapeutics shareholders approve equity plan increase and director elections

Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company with a current market capitalization of $37.64 million, reported Tuesday that shareholders approved all proposals at its Annual General Meeting held Monday, according to a press... Full story

Yahoo Finance • 3 months ago

Akari Therapeutics secures Indian patent for cancer drug payload

BOSTON/LONDON - Akari Therapeutics, Plc (NASDAQ:AKTX), a micro-cap biotech company currently valued at $38 million, has been granted Patent No. 562,919 by Intellectual Property India for its PH1 payload technology, the company announced We... Full story

Yahoo Finance • 3 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a key territory with a rapidly growing incid... Full story

Yahoo Finance • 4 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Access the video here BOSTON and LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the release of... Full story

Yahoo Finance • 4 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of... Full story

Yahoo Finance • 5 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a bi... Full story

Yahoo Finance • 6 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several e... Full story